Remote Ischemic Preconditioning Decreases Adhesion and Selectively Modifies Functional Responses of Human Neutrophils

Shimizu, Mikiko; Saxena, Pankaj; Konstantinov, Igor E.; Cherepanov, Vera; Cheung, Michael; Wearden, Peter D.; Zhangdong, Hua; Schmidt, Michael; Downey, Gregory P.; Redington, Andrew N.

doi:10.1016/j.jss.2008.08.010

Cited by 127 publications

(93 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…40 Cycles of intermittent limb ischaemia provide an acceptable method for inducing cardioprotection, and early proof-of-concept studies have confirmed the effectiveness of remote IPC in cardiac surgery and coronary angioplasty, as evidenced by reduced markers of cardiac injury. 41 A study by Posa et al 42 in pigs showed that IPC (applied using two cycles of 5 min occlusion and 5 min reperfusion of the left anterior descending coronary artery before induction of myocardial infarction) attenuated release of myeloperoxidase and platelet activation after ischaemia-reperfusion, thus improving perfusion.…”

Section: Prevention and Treatment Of Ischaemia-reperfusion Injurymentioning

confidence: 99%

Pharmacological and physical prevention and treatment of no-reflow after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction

Guo

Sheng²,

Xu³

et al. 2013

J Int Med Res

View full text Add to dashboard Cite

After successful primary percutaneous coronary intervention in ST-segment elevation myocardial infarction, adequate myocardial reperfusion is not achieved in up to 50% of patients. This phenomenon of no-reflow is associated with a poor in-hospital and long-term prognosis. Four main factors are thought to contribute to the occurrence of no-reflow: ischaemic injury; reperfusion injury; distal embolization; susceptibility of the microcirculation to injury. This review evaluates the literature, and in particular the clinical trials, concerned with pharmacological and physical methods for prevention and treatment of no-reflow. A number of drugs may improve no-reflow experimentally and clinically, but some have not yet been associated with conclusive improvements in clinical outcome. The complex interacting factors in no-reflow make it unlikely that any single agent will be effective for all patients. Confirmed methods known to be beneficial in the prevention of no-reflow (such as aspirin therapy, chronic statin therapy, blood glucose control, thrombus aspiration in patients with a high thrombus burden and ischaemic preconditioning) should be offered to patients as often as possible, to prevent and treat no-reflow.

show abstract

Section: Prevention and Treatment Of Ischaemia-reperfusion Injurymentioning

confidence: 99%

Pharmacological and physical prevention and treatment of no-reflow after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction

Guo

Sheng²,

Xu³

et al. 2013

J Int Med Res

View full text Add to dashboard Cite

show abstract

“…Similarly, RIC decreased overall levels of interleukin‐1β and interleukin‐6 in a porcine model of lung IRI. In a human forearm endothelial model of IRI, neutrophil adhesion was reduced by RIC, as was phagocytosis 57. Even pro‐inflammatory gene expression in leucocytes appears to be suppressed, while anti‐inflammtory gene expression is up‐regulated 58.…”

Section: Ric: History and Evolutionmentioning

confidence: 97%

Remote ischaemic conditioning: cardiac protection from afar

2015

View full text Add to dashboard Cite

For patients with ischaemic heart disease, remote ischaemic conditioning may offer an innovative, non‐invasive and virtually cost‐free therapy for protecting the myocardium against the detrimental effects of acute ischaemia‐reperfusion injury, preserving cardiac function and improving clinical outcomes. The intriguing phenomenon of remote ischaemic conditioning was first discovered over 20 years ago, when it was shown that the heart could be rendered resistant to acute ischaemia‐reperfusion injury by applying one or more cycles of brief ischaemia and reperfusion to an organ or tissue away from the heart – initially termed ‘cardioprotection at a distance’. Subsequent pre‐clinical and then clinical studies made the important discovery that remote ischaemic conditioning could be elicited non‐invasively, by inducing brief ischaemia and reperfusion to the upper or lower limb using a cuff. The actual mechanism underlying remote ischaemic conditioning cardioprotection remains unclear, although a neuro‐hormonal pathway has been implicated. Since its initial discovery in 1993, the first proof‐of‐concept clinical studies of remote ischaemic conditioning followed in 2006, and now multicentre clinical outcome studies are underway. In this review article, we explore the potential mechanisms underlying this academic curiosity, and assess the success of its application in the clinical setting.

show abstract

Section: Remote Ischemic Conditioningmentioning

confidence: 99%

“…They include the reperfusion-injury salvage kinase [24] and survivor activating factor enhancement [25,26] signaling pathways. Furthermore, RIC modifies systemic inflammatory response [27,28] , prevents endothelial dysfunction [29] and platelet activation [30] following ischemia-reperfusion injury. In experimental studies, RIC has been shown to afford protection against ischemia-reperfusion in the liver [31] , lung [32] , kidney [33] , brain [34] , and heart [29] .…”

mentioning

confidence: 99%

Novel adjunctive treatments of myocardial infarction

Schmidt

Pryds

Bøtker

2014

WJC

View full text Add to dashboard Cite

Myocardial infarction is a major cause of death and disability worldwide and myocardial infarct size is a major determinant of prognosis. Early and successful restoration of myocardial reperfusion following an ischemic event is the most effective strategy to reduce final infarct size and improve clinical outcome, but reperfusion may induce further myocardial damage itself. Development of adjunctive therapies to limit myocardial reperfusion injury beyond opening of the coronary artery gains increasing attention. A vast number of experimental studies have shown cardioprotective effects of ischemic and pharmacological conditioning, but despite decades of research, the translation into clinical effects has been challenging. Recently published clinical studies, however, prompt optimism as novel techniques allow for improved clinical applicability. Cyclosporine A, the GLP-1 analogue exenatide and rapid cooling by endovascular infusion of cold saline all reduce infarct size and may confer clinical benefit for patients admitted with acute myocardial infarcts. Equally promising, three follow-up studies of the effect of remote ischemic conditioning (RIC) show clinical prognostic benefit in patients undergoing coronary surgery and percutaneous coronary intervention. The discovery that RIC can be performed noninvasively using a blood pressure cuff on the upper arm to induce brief episodes of limb ischemia and reperfusion has facilitated the translation of RIC into the clinical arena. This review focus on novel advances in adjunctive therapies in relation to acute and elective coronary procedures.© 2014 Baishideng Publishing Group Inc. All rights reserved.Key words: Myocardial infarction; Primary percutaneous intervention; Coronary artery by-pass graft; Ischemiareperfusion injury; Ischemic preconditioning; Remote ischemic conditioning; Cyclosporine; Cooling; Exenatide Core tip: Patients with ischemic heart disease have a high risk of developing myocardial infarction, which is associated with considerable morbidity and mortality. Limiting the detrimental consequences of myocardial infarction is a major focus of cardiovascular research. Recent clinical studies suggest that novel adjunctive therapy with pharmacological and ischemic conditioning reduce ischemia-reperfusion injury in patients during coronary procedures. In three independent randomized trials, remote ischemic conditioning (RIC) improves clinical outcome in patients undergoing acute or elective percutaneous intervention or coronary artery bypass surgery. RIC can be performed safely and noninvasively by intermittent inflation of a blood-pressure cuff on the upper arm and is easily applicable in most clinical settings. worldwide [1,2] . Since 1990, more people have died from coronary artery disease than any other death cause [3,4] . In China, a staggering 230 million are estimated to suffer from cardiovascular disease, and three million Chinese die of cardiovascular disease annually, accounting for 41% of all deaths [5,6] . In the United States alone, cardiov...

show abstract

Remote Ischemic Preconditioning Decreases Adhesion and Selectively Modifies Functional Responses of Human Neutrophils

Cited by 127 publications

References 29 publications

Pharmacological and physical prevention and treatment of no-reflow after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction

Pharmacological and physical prevention and treatment of no-reflow after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction

Remote ischaemic conditioning: cardiac protection from afar

Novel adjunctive treatments of myocardial infarction

Contact Info

Product

Resources

About